Linking the activity of bortezomib in multiple myeloma and autoimmune diseases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F14%3A33150559" target="_blank" >RIV/61989592:15310/14:33150559 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S1040842814000821" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1040842814000821</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.critrevonc.2014.05.003" target="_blank" >10.1016/j.critrevonc.2014.05.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Linking the activity of bortezomib in multiple myeloma and autoimmune diseases

Popis výsledku v původním jazyce

Since their introduction to the clinic 10 years ago, proteasome inhibitors have become the cornerstone of anti-multiple myeloma therapy. Despite significant progress in understanding the consequences of proteasome inhibition, the unique activity of bortezomib is still unclear. Disappointing results from clinical trials with bortezomib in other malignancies raise the question of what makes multiple myeloma so sensitive to proteasome inhibition. Successful administration of bortezomib in various immunological disorders that exhibit high antibody production suggests that the balance between protein synthesis and degradation is a key determinant of sensitivity to proteasome inhibition because a high rate of protein production is a shared characteristic inplasma and myeloma cells. Initial or acquired resistance to bortezomib remains a major obstacle in the clinic as in vitro data from cell lines suggest a key role for the beta 5 subunit mutation in resistance; however the mutation was not

Název v anglickém jazyce

Linking the activity of bortezomib in multiple myeloma and autoimmune diseases

Popis výsledku anglicky

Since their introduction to the clinic 10 years ago, proteasome inhibitors have become the cornerstone of anti-multiple myeloma therapy. Despite significant progress in understanding the consequences of proteasome inhibition, the unique activity of bortezomib is still unclear. Disappointing results from clinical trials with bortezomib in other malignancies raise the question of what makes multiple myeloma so sensitive to proteasome inhibition. Successful administration of bortezomib in various immunological disorders that exhibit high antibody production suggests that the balance between protein synthesis and degradation is a key determinant of sensitivity to proteasome inhibition because a high rate of protein production is a shared characteristic inplasma and myeloma cells. Initial or acquired resistance to bortezomib remains a major obstacle in the clinic as in vitro data from cell lines suggest a key role for the beta 5 subunit mutation in resistance; however the mutation was not

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/EE.2.3.20.0062" target="_blank" >EE.2.3.20.0062: Levný lék antabus jako protinádorové léčivo: mechanismus účinku a klinické testy</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Critical Reviews in Oncology / Hematology

ISSN

1040-8428

e-ISSN

—

Svazek periodika

96

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

61-70

Kód UT WoS článku

000344514300001

EID výsledku v databázi Scopus

—